| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 2
| Issue : 1 | Page : 3-7 |
|
|
Severe community-acquired pneumonia: Severity and management
Adamantia Liapikou1, Catia Cilloniz2
1 Sotiria Chest Diseases Hospital, Mesogion 152, 11527 Athens, Greece
2 Department of Pneumology, Hospital Clinic, Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona, Barcelona, Spain
Correspondence Address:
Adamantia Liapikou
Sotiria Chest Diseases Hospital, Mesogion 152, 11527 Athens
Greece
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2225-6482.153855
|
|
|
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide. "Severe CAP'' (sCAP) identifies a group of patients who have severe disease and require Intensive Care Unit admission. Recommendations for antibiotic treatment for sCAP are based on illness severity, frequency of specific pathogens and local microbial resistance patterns. The challenges to patient management include the emergence of the high prevalence of multidrug-resistant in CAP, mainly from institutionalizing patients. A new approach is the evaluation of biomarkers as C-reactive protein, procalcitonin on the diagnosis, prognosis and therapy duration of sCAP with promising results . Implementation of guidelines for CAP treatment should be emphasized in order to increase survival. The benefits of steroid use in patients with severe pneumonia have not been proven yet by current literature. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
